Adult Open Studies

COVID-19 - APPOINTMENTS AND PROCEDURES

Your health and safety is still our top priority. Appointments are available as video visits, phone calls or in-person visits as needed, with the same safe, world-class care you expect.

Schedule Now

Biology

LLUCC-BIOSPECIMEN LABORATORY - SPECIMEN COLLECTION

Loma Linda University Cancer Center Biospecimen Laboratory Specimen Collection Protocol

Mark E. Reeves, MD, PhD

Brain

SWOG-NRG-BN001

Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT02179086

Joseph Kang, MD

Investigator Initiated-AXUMIN

Differentiating glioma recurrence from treatment-induced necrosis using 18F-fluciclovine (anti-18f-facbc) PET and Multiparametric MR Imaging
https://clinicaltrials.gov/ct2/show/NCT03925675

Warren Boling, MD

SWOG-EAF151

Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT03115333

Muhammad Kamal, MD

Breast

NSABP-B51

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT01872975

Sharon Lum, MD

Investigator Initiated GRASP-CIPN

A Pilot Study of Intraneural Facilitation for Managing Chemotherapy-Induced Peripheral Neuropathy.
https://clinicaltrials.gov/ct2/show/NCT03272919

Gayathri Nagaraj, MD

SWOG-S1418-BR006

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy Cancer
https://clinicaltrials.gov/ct2/show/NCT02954874

Gayathri Nagaraj, MD

SWOG-BR004

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT03199885

Gayathri Nagaraj, MD

SWOG-A011202

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT01901094

Sharon Lum, MD

GI

Colon

SWOG-S0820

Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification
https://www.clinicaltrials.gov/ct2/show/NCT03365882

Chung-Tsen Hsueh, MD, PhD

SWOG-S1613

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
https://www.clinicaltrials.gov/ct2/show/NCT01349881

Chung-Tsen Hsueh, MD, PhD

Esophagus

Radiation Medicine

A phase II trial of proton-chemotherapy (PCT) for resectable esophageal or esophagogastric junction cancer
https://clinicaltrials.gov/ct2/show/NCT01684904

Gary Yang, MD

Liver

Radiation Medicine

Phase I/II Trial of Stereotactic Body Proton Therapy (SBPT) for Patients with Liver Metastases
https://clinicaltrials.gov/ct2/show/NCT01697371

Gary Yang, MD

QED-QBGJ398-301

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial
https://clinicaltrials.gov/ct2/show/NCT03773302

Chung-Tsen Hsueh, MD, PhD

NeuWave- NEU-2017-04

A Multicenter Observational Registry to Develop Abation Parameter Guidance for Microwave Liver Ablation of Soft Tissue Lesions
https://clinicaltrials.gov/ct2/show/NCT04107766

Roger Tomihama, MD

Pancreas

Investigator Initiated

A Phase II Trial of Pre-operative Chemotherapy (with Gemcitabine and Nab-paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients with Resectable Pancreatic https://clinicaltrials.gov/ct2/show/NCT03492671

Naveenraj Solomon, MD

GU

Prostate

Radiation Medicine

A prospective comparative study of outcomes with proton and photon radiation in prostate cancer
https://clinicaltrials.gov/ct2/show/NCT00831623

Jerry Slater, MD

Pfizer-C3441021

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT03395197

John Wong, MD

Urethra

SWOG-A031501

hase III randomized “Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locally ADva nced urOthelial caRcinoma” (AMBASSADOR) versus observation
https://clinicaltrials.gov/ct2/show/NCT03244384

John Wong, MD

GYN

Multiple

Investigator Initiated-Paclitaxel

Conventional prophylactic regimen of oral dexamethasone versus short-course intravenous dexamethasone in preventing paclitaxel-related hypersensitivity reactions in gynecologic-oncology patients: A prospective, randomized, open-label study
https://clinicaltrials.gov/ct2/show/NCT03598426

Linda Hong, MD

SWOG-GY019

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
https://clinicaltrials.gov/ct2/show/NCT04095364

JYevgeniya Ioffe, MD

Ovarian

Investigator Initiated HIPEC

Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT02672098

Mazdak Momeni, MD

Cervical

GOG-0263

Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
https://clinicaltrials.gov/ct2/show/NCT01101451

Yevgeniya Ioffe, MD

Uterine

GOG-0238

A Randomized Trial Of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin In Patients With Pelvic-Only Recurrence Of Carcinoma Of The Uterine Corpus
https://clinicaltrials.gov/ct2/show/NCT00492778

Linda Hong, MD

Leukemia

SWOG-A041701

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
https://clinicaltrials.gov/ct2/show/CT03701308

Muhammad O. Kamal, MD

Lung

SWOG-LU003

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
https://clinicaltrials.gov/ct2/show/NCT03737994

Hamid Mirshahidi, MD

SWOG-A151216

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
https://clinicaltrials.gov/ct2/show/NCT02194738

Hamid Mirshahidi, MD

SWOG-E4512

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
https://clinicaltrials.gov/ct2/show/NCT02201992

Hamid Mirshahidi, MD

SWOG-LUNGMAP

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
http://clinicaltrials.gov/ct2/show/NCT02154490

Hamid Mirshahidi, MD

SWOG-A081105

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
https://clinicaltrials.gov/ct2/show/NCT02194738

Hamid Mirshahidi, MD

Lymphoma

SWOG-A051301

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype
https://clinicaltrials.gov/ct2/show/NCT02443077

Muhammad O. Kamal, MD

SWOG-S1608

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03269669

Muhammad O. Kamal, MD

Melenoma

SWOG-S1801

A Phase II Randomized Study of Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma (NCT #03698019)
https://clinicaltrials.gov/ct2/show/NCT03698019

Mark E. Reeves, MD, PhD

Multiple

SWOG-EAY131-MATCH

Molecular Analysis for Therapy Choice (MATCH)
https://clinicaltrials.gov/ct2/show/NCT02465060

Gayathri Nagaraj, MD

SWOG-S1609

DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
https://clinicaltrials.gov/ct2/show/NCT02834013

John Wong, MD

COG-AGCT1532

A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with Intermediate and poor-risk metastatic germ cell tumors
https://clinicaltrials.gov/ct2/show/NCT02582697

John Wong, MD

Registry

Radiation Medicine

Radiation Medicine Patient Registry
https://clinicaltrials.gov/ct2/show/NCT02436941

Jerry Slater, MD

Penn State-Colon Registry

Prospective observational database of patients with colon cancer at risk of peritoneal recurrence

Maheswari Senthil, MD

Soft Tissue Sarcoma

Radiation Medicine

A phase II study of preoperative proton therapy in soft tissue sarcomas of the extremities and body wall
https://clinicaltrials.gov/ct2/show/NCT01819831

Gary Yang, MD

Transplant

ATARA - ATA129-EBV-302

Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
https://clinicaltrials.gov/ct2/show/NCT03394365

Hamid Mirshahidi, MD

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050

Temporary Network Interruption

Keyword Search

Services & Treatments

Provider Search

Location Search

Adult Open Studies